1. Scrip
  2. >>Business

Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I

 
• By Jessica Merrill

Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.

Wooden little men holding hands on wooden boards background. Symbol of friendship, love and teamwork
Sanofi and Kymera partnered on a protein degrader for immunology and inflammation • Source: Shutterstock

Sanofi is partnering with Kymera Therapeutics, LLC. in a budding area of drug development – protein degradation – as it looks for new opportunities to expand in immunology and inflammation. The companies announced a collaboration on 9 July in which Sanofi agreed to pay Kymera $150m up front for rights to develop and commercialize first-in-class protein degrader therapies targeting interleukin-1 receptor associated kinase 4 (IRAK4) in patients with immune-inflammatory diseases and a second earlier-stage program.

In addition to the upfront payment, Sanofi also agreed to pay more than $2bn in potential development, regulatory and sales

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Sarepta Slammed By Double Blow: Elevidys Sales Miss, Prasad’s CBER Appointment

 
• By Mandy Jackson

Sarepta’s stock price was battered after Vinay Prasad was appointed to lead the US FDA’s CBER, then the company’s shares were bruised when Q1 Elevidys sales came in below consensus.

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

BeiGene To Trade Beach For Chalet In Swiss Redomiciling As BeOne

 
• By Alaric DeArment

The biotech saw a slight quarter-over-quarter decline in sales from the BTK inhibitor Brukinsa, which it attributed to seasonality, while revenues overall missed some analyst estimates.